A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...
Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback